EN | UA
EN | UA

Help Support

Back

Safety and efficacy of tildrakizumab for psoriasis management

Safety and efficacy of tildrakizumab for psoriasis management Safety and efficacy of tildrakizumab for psoriasis management
Safety and efficacy of tildrakizumab for psoriasis management Safety and efficacy of tildrakizumab for psoriasis management

This real-world study was performed to determine safety and effectiveness of tildrakizumab (interleukin 23p19-inhibitor) to manage psoriasis in daily practice.

See All

Key take away

In people having moderate-to-severe plaque psoriasis, tildrakizumab showed good safety and efficacy. Tildrakizumab therapy led to a rapid decline in disease severity and itch and improved health-related quality of life. 

Background

This real-world study was performed to determine safety and effectiveness of tildrakizumab (interleukin 23p19-inhibitor) to manage psoriasis in daily practice.

Method

In this prospective single-center cohort study, psoriasis people eligible for systemic therapy were incorporated into Kiel Tildra Cohort (KTC). The KTC included 150 people differing substantially from those in the reSURFACE trial program. Participants were followed utilizing routine evaluation of psoriasis area and severity index (PASI), safety, itch visual analog scale (VAS), body surface area, and dermatology life quality index (DLQI). The data of KTC were compared to respective phase III trials.

Result

In comparison with phase 3 reSURFACE studies, the KTC exhibited a high rate of previous systemic (87.3%) and biologic (31.8%) therapy and comorbidity. As a result of the best practice approach, the baseline PASI was reported to be lower in KTC. However, DLQI was comparable in both groups.

As noted, week 28, week 52 and week 76 were completed by 126, 92, and 58 participants respectively. A constant improvement was noted in DLQI, PASI, itch, and body surface area from baseline until week 76. No significant laboratory abnormality was noted.

Conclusion

People managed in routine practice with tildrakizumab therapy differed considerably from the phase III trial. In spite of systemic pre-therapy and raised comorbidity, tildrakizumab illustrated comparable safety and effectiveness in KTC. Prospective cohort studies are appropriate tools for generating real-world evidence before there is an availability of registry data. 

Source:

Dermatology

Article:

Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients

Authors:

Katharina A Drerup et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru en
Try: